Cyclophosphamide

PD-L1 Gene Mutation

Sarah GoldbergSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the PD-L1 Gene Mutation cohort.

Asset / Sponsor	Phase	Rating
Durvalumab Shirish M Gadgeel	Phase 2	CCC
Carboplatin Shirish M Gadgeel	Phase 2	CCC
Atezolizumab Consorzio Oncotech	Phase 2	CCC
Pembrolizumab Sarah Goldberg	Phase 2	CCC
Epirubicin Sarah Goldberg	Phase 2	CCC
Sitravatinib Sarah Goldberg	Phase 2	CCC

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

mycosis fungoidesDormant

BBB

Indicative ·

78 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.